DLX 0110
Alternative Names: DLX0110Latest Information Update: 07 Aug 2007
At a glance
- Originator DELEX Therapeutics
- Class
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Pain
Most Recent Events
- 04 May 2005 DELEX Therapeutics has been acquired by YM BioSciences
- 27 Aug 2003 Preclinical trials in Pain in Canada (unspecified route)